US › Healthcare

SAB Biotherapeutics Inc (SABS)

US · Healthcare · Biotechnology

$3.85+1.58%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$0
Net profit
$-18.9M
Profit YoY
-263.1%
EPS
$-0.35
EPS estimate
$-0.21

EPS came in at -0.35 against a street estimate of -0.21 — a miss of 69.4%.

Key statistics

Market cap
$273.0M
Forward P/E
0.0
P/B
1.20
Book value
$3.00
EPS (TTM)
$-0.58
52-week high
$5.15
52-week low
$1.85
50-day MA
$3.66
200-day MA
$3.73
Beta
0.53

Analyst view

Analysts rate SAB Biotherapeutics Inc a strong buy (5 buy, 0 hold, 0 sell out of 5) with an average price target of $11.18.

Shareholding

Insiders
0.84%
Institutions
92.39%

Largest institutional holders

FundStake
Vivo Capital, LLC14.94%
Caligan Partners LP10.42%
Perceptive Advisors LLC8.41%
COMMODORE CAPITAL LP5.76%
RA Capital Management, LLC5.76%
Balyasny Asset Management LLC4.92%
Adage Capital Partners Gp LLC4.45%
Millennium Management LLC3.97%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for SAB Biotherapeutics Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.